using these pill bottles prompts behavior. If the study did not have the budget for these devices, I would just state that self-report scales were used and recognize it as a limitation. 11. Many of these dimensions have been reported in prior research. So Page 10 line 8 is inaccurate. 12. Page 10 Line 38 does not make sense. In qualitative research you complete interviews until data saturation is reached. There is no way of knowing how many people this will include. 13. An example of the questions asked is needed. It depends on the qualitative research method used, but often the data collection is not informed by the literature because it is thought to bias the findings. 14. There is not research question for the qualitative aspect of the project. 15. The questions presented in the data analysis (line 29) portion of the qualitative analysis are not appropriate for qualitative inquiry. The results are not going to be generalizable beyond those interviewed persons. Typically qualitative inquiry is used to describe or explore an area of interest that is not well studied. 16. I think the study needs to be completed to contribute significantly to the literature in this area. Similar studies have been conducted; yet verification of other study findings would be interesting. Just presenting the protocol provides very little insight into this health care problem. Similarly, there are a number methodologic issues with the protocol. 
REVIEWER

THE STUDY
In the manuscript "a mixed methods study to investigate medication adherence in patients with RA of White British and South Asian origin" Karim Raza describes the protocol of a study aiming to assess the relationship between adherence to medicines and biopsychosocial variables. This is a very relevant topic, as non adherence in RA might be associated with less effective therapy and consequently possible also more disease activity. As there is existing literature that adherence differs between several ethnical groups, the aim is of study is therefore also relevant. However, I would like to make some methodological remarks on the design of the study: 1) The introduction elegantly illustrates the importance of adherence, and the importance for a more race specific approach. However, a more structured introduction illustrating why some variables are used in this study (and others not) wiill help the reader to rationalize the questionnaires used in this study. It is for example interesting to know why the IPQ is used, why the HAQ instead of DAS28 I used, and why the SIMS is used . Probably also the reimbursement, social status and type of medication are also relevant.
2) The method of determining the outcome measurement is very patient centered. However, besides patient preference, the validity of the tools and it's discrimative power is also essential. 
VERSION 1 -AUTHOR RESPONSE
Reviewer 1
Comment 1:
The introduction elegantly illustrates the importance of adherence, and the importance for a more race specific approach. However, a more structured introduction illustrating why some variables are used in this study (and others not) will help the reader to rationalize the questionnaires used in this study. It is for example interesting to know why the IPQ is used, why the HAQ instead of DAS28 used, and why the SIMS is used.
The text has been amended to the following and changes are highlighted in yellow (page 10).
There are very few studies that provide evidence regarding illness perception amongst RA patients of South Asian origin. The illness perception tool has five discrete attributes (identity, cause, timeline, consequences, cure and control), that patients tend to have about their condition (their illness perception) score ranging from a five -point scale, where 1 = strongly disagree and 5 = strongly agree).These help predict health behaviours such as medication adherence. For example, medication adherence in patients with hypercholesterolemia has been shown to be related to beliefs that the disease has severe coronary consequences. Hypertensive patients who believe that their condition is chronic are more likely to adhere to their antihypertensive medication than those who believe it to be an acute condition. The latter group of patients may view themselves to be cured. Looking at the association of the IPQ and MARS will be useful to determine associations with medication adherence.
Authors' 'response:
We will be using both the HAQ and DAS28 as disease measures. DAS28 score will be collected as a clinical routine measure. The justification of HAQ has been changed in the text to the following: (page 7)
The HAQ will be used to assess functional disability as we have shown that patients with negative beliefs have a worse function scores. Thus, the association of HAQ with MARS may provide useful data.
(Page 9)
Patients usually require a rationale for their medication before following advice about taking it. It is well known that 40% of patients on chronic medication do not take their medication as prescribed. It is likely that medication adherence is improved if patients are provided with information which addresses the issues they want to know about in a way that is comprehensible. Patient satisfaction with information can be measured using the Satisfaction with Information about Medications questionnaire (SIMS). This questionnaire has two subscales -action and usage of drugs (nine items), and potential problems (eight items). Those who report that the information is "about right" or indicate "none needed" will be classified as satisfied (scored 1). Those who report that the information is "too much", "too little" or indicate "none received" will be classified as dissatisfied (scored 0). Responses will be recorded on a likert scale (too much -none needed) by capturing these data we will be able to assess the relationship between satisfaction with information about medication and adherence in our study population.
Comment 2:
The method of determining the outcome measurement is very patient cantered. However, besides patient preference, the validity of the tools and its discrimative power is also essential. More information about the validation of the MARS (more than in the cited reference) is necessary.
The text has been amended to the following and changes are highlighted in yellow (page 7).
The valid and reliable Medication Adherence Report Scale (MARS) will be used to capture data to address the relationship between adherence to medicines used in RA and potential explanatory variables (identified from factors that are known to influence adherence) in patients with RA of White British and South Asian origin. MARS is a 5 -item self-report scale for assessment of adherence to medication (e.g. I forget to take them, and I alter the dose), The items are rated on a 5 point Likert scale, ranging from 1=very often to 5=never.
Comment 3:
How are the patients of the steering group selected? How was decision process operationalized?
Authors' response:
We ensured that patients who were recruited to the steering group were not known to the researchers in a clinical capacity. Patients themselves chaired and led the patient user group. Further, only one researcher (KK) was present to document the discussions. The text of the manuscript has been amended as follows: (page 11)
The study design was presented to the rheumatology departmental patient User Group. An invitation to join the project Steering Group was offered to all patients and four (two White British and two South Asian patients) joined this Group. None of these patients' rheumatoid arthritis was being treated by the researchers from a clinical perspective.
Comment 4:
The sample size calculation is not completely clear. Which correlation technique will be used? The primary questions on page 10 correlate BMQ necessity and concerns with adherence. Which of these (sub) scales is used for the sample size calculation? Is this calculation sufficient to discriminate between the ethnical classes? How many variables will be included in the model? And does the model have enough power for all these variables?
Authors' response:
Given the limited evidence in the area of adherence in South Asian patients with RA we did not consider we had sufficient data to be able to calculate the sample size required to detect the differences in adherence between the ethnic groups. We also did not know how many variables would be included in the model until the univariate was undertaken. However, we are aware of the dangers of including too many variables.
The text has been amended to the following and changes are highlighted in yellow (page 12).
The sample size of 176 (88 patients from each ethnic group) will detect with at least 80% power a significant Pearson correlation coefficient at the 5% level if the true significant correlation of adherence and beliefs about medicines is less than or equal to -0.21 or greater than or equal to +0.21. This calculation has been based on a previous study that investigated the relationship between beliefs about medicine and adherence 1 . In this paper the authors found a Pearson correlation coefficient of 0.21 between neccessity score and adherence and a Pearson correlation coefficient of -0.33 between concern score and adherence. Thus, the sample size will enable us to detect correlations of these magnitudes with at least 80% power.
Comment 5:
How will non-parametric data (like the MEMS-score) be handled?
Authors' response:
We state in our paper (page 11) that we will not use MEMS.
Comment 6:
How is ethnicity taken into account in the in-depth qualitative interviews? How is the maximum variety approach operationalized?
Authors' response:
Further to reviewers' comment. The maximum variety approach will be operationalized by inviting patients for interview who will be selected according to the adherence score. This will be determined by MARS i.e. lower tertile and upper tertile (stated on page 13).
The text has been amended to the following and changes are highlighted in yellow (page 13).
In each group (patients with good and poor adherence) there will be a mixture of White and South Asian patients.
Comment 7:
Is the MARS discriminative enough to separate adherent and non-adherent patients based on tertiles? My experience is that most patients have scores of 23, 24 or 25.
Authors' response:
Horne et al (Chronic Illness, 2010) used the MARS scores in patients with hypertension and, in agreement with the experience of Reviewer 1, they found that MARS scores were very high. In the high adherence group there were 188 patients who had a mean MARS score of 29 or more out of 30 and in the low adherence group there were 35 who had a mean MARS score of less than 29 out of 30. The authors found significant differences between these two groups, even though some of the 35 in the low adherence group would have had MARS scores in the high twenties. Furthermore, Horne et al (Journal of Psychosomatic, 1999) showed that higher concern score was correlated with a lower MARS score. Our work has highlighted that South Asian patients had higher specific concern about DMARDs (Kumar et al, Rheumatology, 2008 ) and so we expect South Asian patients to have a greater spread of MARS scores. We therefore believe that tertiles will discriminate between adherent and nonadherent but, if necessary, we will sample from, for example, the lowest quintile rather than the lower tertile.
Comment 8:
How will the qualitative approach be validated by a second independent person?
The text has been amended and changes are highlighted in yellow (page 14).
The transcripts will be read and independently coded by two other members of the research team a clinican, (PG) and a medical sociologist, (SG) to ensure an inter-disciplinary perspective. Discussion will be held between the team to finalise the themes for coding.
Comment 9:
The association between biopsychosocial parameters and adherence is currently not very consistent and often very weak. However in the introduction some associations are introduced as strong relationships like disease severity (line 52), beliefs (line 42) and factors like age, income, education level etc. These associations are still inconclusive or very weak.
Authors' response:
We agree with these comments and have amended the text as follows: (page 5) Other factors may be associated with adherence including age, income, level of education, knowledge of disease and satisfaction with information about medicines. Several authors have suggested that patients' beliefs about medicines play an important role in medication adherence in chronic diseases.
For example, in rheumatology, Neame and Hammond found that concerns about medicines were higher in non-adherent than adherent RA patients and were associated with feelings of helplessness.
Patients with higher levels of concerns were those who reported more adverse effects from DMARDs.
Also, disease severity plays a key role in patients' decisions to either take or not take their treatments.
Reviewer 2: Comment 1:
Overall: Results would be helpful to contribute to the knowledge in this area. 
Comment 6:
Line 33 Page 4-Factors and theories are presented. There is not discussion of their applicability in an RA population.
Authors' response:
This introduces the concepts which are further developed on (pages 5-6). Patients' beliefs about the meaning of symptoms were important when deciding to seek medical help.
This was sometimes related to a perception that their symptoms represented God's punishment and medical help seeking was thus often delayed, contributing towards delays in initiating treatment.
Comment 7:
Page 5 second paragraph-This paragraph seems to describe the literature about medication adherence in RA patients; although it not clear if the information presented is specific to patients with RA. I think this paragraph would be more effective at building the case for the study by offering what is known, unknown and where there are conflicting results.
